New injectable weight-loss drugs are changing waistlines, NHS budgets and expectations – but they come with an awkward catch.
Patients on blockbuster obesity injections such as Wegovy and Mounjaro can lose a striking amount of weight. Once the jabs stop, though, the weight tends to rush back far more quickly than doctors and health economists had planned for.
Weight-loss injections that looked almost miraculous
In trials, weekly injections like semaglutide (Wegovy), tirzepatide (Mounjaro) and liraglutide (Saxenda) have been hailed as game changers. Participants typically lost 15–20% of their body weight – far beyond what most diet and exercise programmes manage.
These drugs are part of a class called GLP‑1 analogues. They act on hormones that regulate appetite and the way the body handles blood sugar. Many patients say they feel full sooner and think about food less.
In the UK, around one person in 50 is now using these injections. Most are not getting them through the NHS. Roughly 90% are paying privately, at around £120–£250 a month. For many households, that is the equivalent of a second rent or mortgage payment.
The financial hit shows up quickly. More than half of people who start these drugs stop within a year, largely because they can no longer afford them. Until recently, doctors did not have solid data on what happens next. A new analysis published in the British Medical Journal now fills that gap, and the picture is sobering.
Clinical data suggest that, once treatment stops, people regain almost all the weight they lost within about 18 months.
Weight comes back – and it comes back fast
Researchers reviewing the available trials found a clear pattern. After stopping GLP‑1 injections, participants steadily put weight back on. By a year and a half, most were back to their starting weight, or close to it.
The speed of the rebound is striking. Compared with people who lose weight through structured diet and physical activity programmes, those coming off injections regain weight around four times faster.
The benefits that made these drugs so attractive for health services also fade. While on treatment, patients typically see:
➡️ My stomach is firmer and my waist is slimmer: pilates moves that work wonders for women over 60
➡️ This toothpaste that protects the microbiome slows harmful bacteria and preserves oral balance
➡️ Russia Prepares To “Release The Kraken” In The Baltic Sea To Secure A Vital Export Lifeline
➡️ This pillar of osteoarthritis treatment shows more modest results than expected
➡️ In the frozen depths of the Arctic, an unexpected answer to climate change emerges
➡️ Hairstyles at 70: this mistake makes your face look much older
- lower blood pressure
- improved cholesterol levels
- better blood sugar control
Once the jabs stop, those markers drift back to where they were before treatment. For a health system that is funding the drugs mainly to prevent heart attacks, strokes and diabetes complications, that raises hard questions.
The health gains seem tightly tied to staying on the injection; stop the drug, and the numbers slide back.
Lifetime treatment or short-term boost?
These findings suggest something uncomfortable: for many people, obesity injections may have to be taken long term, possibly for life, to sustain both weight loss and health improvements.
Some private clinics try to cushion that reality by bundling the injections with intensive lifestyle support – regular coaching, diet plans, and exercise guidance. The BMJ analysis found that such support can add an extra 4.6 kg of weight loss on average during treatment.
Yet there is no convincing evidence that extra coaching, either during or after treatment, slows the speed of weight regain once the drug is stopped. That leaves patients and doctors with a tough choice: continue paying, or brace for a rebound.
Who gets access – and who is left out?
Obesity does not affect all groups equally. Rates are higher in more deprived communities, where sedentary jobs, cheaper calorie-dense foods and limited access to green space collide. Those same communities are the least able to afford private treatment.
The NHS is now rolling out GLP‑1 injections, but under tight rules. At present, they are offered only to people with severe obesity – typically a body mass index (BMI) over 40 – and at least one serious obesity-related condition, such as high blood pressure or type 2 diabetes.
| Category | Typical access to GLP‑1 injections in the UK |
|---|---|
| Severe obesity with complications | May qualify for NHS-funded treatment |
| Obesity without major complications | Generally private pay only |
| Overweight, high health risk | Lifestyle support; drug treatment rarely funded |
That means a large group of people – those whose weight is high enough to damage their health but not high enough for current NHS thresholds – are mostly excluded unless they pay personally. For them, the new drugs remain more a symbol of what might be possible than a realistic option.
Cost-effectiveness model under pressure
The National Institute for Health and Care Excellence (NICE) signed off these drugs for NHS use based on cost-effectiveness models. Those models assumed a two-year course of treatment, and that weight would return gradually over about three years after stopping.
The new data challenge those assumptions. If weight rebounds almost fully in 18 months and blood pressure and cholesterol drift back just as quickly, then the benefits of a short-term course look far smaller than NICE originally calculated.
Faster regain means fewer years of better health for every pound spent, which changes the maths for the NHS.
Extending treatment indefinitely might preserve the benefits, but at a steep price. Even if future generic or tablet forms become cheaper, they are unlikely to be inexpensive in the near term. Health economists now need to revisit the numbers using real-world patterns of stopping and starting, rather than tidy trial timelines.
Old-school programmes still matter
For people who do not meet NHS criteria, or who cannot afford private prescriptions, more traditional weight-management programmes remain the main option.
One approach attracting renewed interest is “total diet replacement”: nutritionally complete soups and shakes replacing normal meals for 8–12 weeks, followed by a structured food reintroduction. These programmes can achieve weight loss similar to that seen with GLP‑1 drugs, at a fraction of the cost.
Group-based schemes such as WeightWatchers or Slimming World deliver more modest average weight loss, but they tend to be cheaper per person. Studies suggest they can still represent good value for money for the NHS, particularly when they prevent or delay type 2 diabetes.
What GLP‑1 actually means
GLP‑1 stands for “glucagon-like peptide‑1”. It is a hormone released in the gut after eating. It signals to the brain that we are full and slows the movement of food through the stomach.
Drugs like semaglutide mimic this hormone. They reduce appetite and can change the way the reward system in the brain responds to food, which is why many users report fewer cravings. They also help the pancreas release insulin in a more controlled way, which stabilises blood sugar.
When the injections stop, those signals fade. The body’s original appetite and energy-balance systems reassert themselves, often strongly. For people who have lived with obesity for years, those biological drives are powerful, and that may explain the rapid weight regain seen in trials.
Real-life scenarios: what patients are facing
Consider a 45‑year‑old office worker with obesity and high blood pressure. On a GLP‑1 injection, she loses 20 kg over a year, her blood pressure normalises, and she comes off one of her medications. After 12 months, the private prescriptions become too expensive. She stops. Over the next year and a half, she puts most of the 20 kg back on. Her blood pressure climbs, and the heart disease risk the NHS briefly reduced returns.
Another patient with similar weight but without major complications is just below the NHS threshold for treatment. He tries a 12‑week total diet replacement programme through his GP. He loses slightly less weight than his neighbour on injections but pays far less. If he can keep a portion of that loss off through ongoing support, the long-term health gains for the health service could rival those of the drugs at a far lower cost.
Risks, benefits and combined approaches
GLP‑1 injections are not magic bullets, but they can be powerful tools. They are particularly useful for people with severe obesity and serious complications, where rapid, substantial weight loss can quickly reduce the risk of heart disease and diabetes complications.
Side effects matter as well. Many users report nausea, vomiting, diarrhoea or constipation, especially when doses increase. Most effects are manageable, but some people stop treatment because they feel unwell.
Some specialists are now looking at hybrid strategies: using GLP‑1 drugs to jump-start weight loss, then transitioning to intensive lifestyle programmes while tapering the dose, in the hope of slowing the rebound. The evidence for this staged approach is still thin, yet it reflects a broader shift in thinking – towards seeing the injections not as standalone miracles but as part of longer, more complex obesity care.
For patients and health systems, the message is blunt. These drugs work while you take them, and they change the numbers on the scale impressively. Once the injections stop, biology fights back fast, and the bill for long-term use is only just starting to be counted.